A clinical study to determine the effect of mobile phone application in improving compliance to prescribed drugs among patients with chronic diseases.
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]Health Condition 2: C921- Chronic myeloid leukemia, BCR/ABL-positiveHealth Condition 3: I10- Essential (primary) hypertensionHealth Condition 4: C50- Malignant neoplasm of breastHealth Condition 5: C34- Malignant neoplasm of bronchus andlungHealth Condition 6: C15-C26- Malignant neoplasms of digestive organsHealth Condition 7: E11- Type 2 diabetes mellitus
- Registration Number
- CTRI/2020/10/028420
- Lead Sponsor
- JIPMER Puducherry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Diabetes mellitus and Systemic hypertension:
1. Patients with type 2 diabetes (T2DM) aged greater than 18years irrespective of gender, who are on stable dose of anti-diabetic medication for at least 1 month
2. Patients with Systemic hypertension aged greater than 18years irrespective of gender, who are on stable dose of antihypertensive medication for at least 1 month
3. Patients with concomitant type 2 diabetes and systemic hypertension
4. Patients who are able to read Tamil/ English/ Hindi
5. Patients who are owning and operating a smartphone at least for 3 months
6. Patients who are using the smartphone daily, having the phone within reach and checking it atleast three times a day
7. Patients who have not used any medication adherence application till now
Cancer:
8. Patients with gastro-intestinal malignancies receiving capecitabine
9. Patients with chronic myeloid leukemia receiving imatinib
10. Patients with breast cancer receiving hormonal therapy (tamoxifen)
11. Patients with lung cancer receiving gefitinib
12. Patients with Acute lymphoid leukemia receiving methotrexate/ 6-mercaptopurine
13. Patients who are able to read Tamil/ English/ Hindi
14. Patients who are owning and operating a smartphone for at least 3 months
15. Patients who are using the smartphone daily, having the phone within reach and checking it atleast three times a day
16. Patients who have not used any medication adherence application till now
Diabetes mellitus and Systemic hypertension:
1. Diabetic patients on insulin therapy
2. Patients with secondary hypertension or gestational hypertension
3. Patients with hypertensive emergency/ urgency
4. Pregnant or lactating women
5. Patients with hepatic/ renal impairment
6. Patients with h/o Coronary artery disease, cerebrovascular disease, stroke, Myocardial Infarction(MI) in the past 3 months
7. Patients who had participated in any other trials in the past 3 months
8. Patients with h/o surgery in the past 3 months or planning for surgery in the next 3 months
9. Patients on herbal medications
Cancer:
10. Pregnant or lactating women
11. Patients with h/o surgery in the past 3 months or planning for surgery in the next 3 months
12. Patients with hepatic/ renal impairment
13. Patients with h/o Coronary artery disease, cerebrovascular disease, stroke, MI in the past 3 months
14. Patients who had participated in any other trials in the past 3 months
15. Patients on herbal medications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adherence to medication (measured using pill count and Medication Adherence Rating Scale(MARS) /Morisky Medication Adherence Scale-8(MMAS-8)) in patients with chronic diseases (Diabetes Mellitus/ Hypertension/ Cancer)Timepoint: After 3 months
- Secondary Outcome Measures
Name Time Method Diabetes mellitus / Systemic hypertension: <br/ ><br>To determine the <br/ ><br>Changes in HbA1c levels in diabetes patients <br/ ><br>Changes in systolic and diastolic BP values in hypertension patients <br/ ><br>Changes in HbA1c levels, systolic and diastolic BP values in patients with concomitant diabetes and hypertension <br/ ><br>Changes in lipid profile in patients with concomitant dyslipidemia <br/ ><br>Cancer: <br/ ><br>Disease progression/ occurrence of metastasis/ recurrence of tumor in intervention and control group. <br/ ><br>Timepoint: 3 months